Literature DB >> 9389389

Potentiation of anandamide hypotension by the transport inhibitor, AM404.

A Calignano1, G La Rana, M Beltramo, A Makriyannis, D Piomelli.   

Abstract

The putative endogenous cannabinoid, anandamide (0.2-2 mg/kg i.v.), decreased systemic blood pressure dose-dependently in anesthesized guinea pigs. These effects were prevented by the CB1 cannabinoid receptor antagonist SR141716A [N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-me thyl-1H-pyrazole-3-carboxamide x HCl] at the dose of 0.2 mg/kg i.v. The vasodepressor responses to anandamide were significantly potentiated and prolonged by a novel inhibitor of carrier-mediated anandamide transport, N-(4-hydroxyphenyl) arachidonylethanolamide (AM404) (10 mg/kg, i.v.). These results suggest that anandamide transport participates in terminating the vascular actions of anandamide.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9389389     DOI: 10.1016/s0014-2999(97)01297-1

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  25 in total

1.  Characterization of palmitoylethanolamide transport in mouse Neuro-2a neuroblastoma and rat RBL-2H3 basophilic leukaemia cells: comparison with anandamide.

Authors:  S O Jacobsson; C J Fowler
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

2.  2012 Division of medicinal chemistry award address. Trekking the cannabinoid road: a personal perspective.

Authors:  Alexandros Makriyannis
Journal:  J Med Chem       Date:  2014-05-01       Impact factor: 7.446

3.  Anandamide-induced relaxation of sheep coronary arteries: the role of the vascular endothelium, arachidonic acid metabolites and potassium channels.

Authors:  J Grainger; G Boachie-Ansah
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

Review 4.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 5.  Cellular accumulation of anandamide: consensus and controversy.

Authors:  Cecilia J Hillard; Abbas Jarrahian
Journal:  Br J Pharmacol       Date:  2003-09-01       Impact factor: 8.739

6.  The cannabinomimetic arachidonyl-2-chloroethylamide (ACEA) acts on capsaicin-sensitive TRPV1 receptors but not cannabinoid receptors in rat joints.

Authors:  Chris L Baker; Jason J McDougall
Journal:  Br J Pharmacol       Date:  2004-07-26       Impact factor: 8.739

7.  Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension.

Authors:  Sándor Bátkai; Pál Pacher; Douglas Osei-Hyiaman; Svetlana Radaeva; Jie Liu; Judith Harvey-White; László Offertáler; Ken Mackie; M Audrey Rudd; Richard D Bukoski; George Kunos
Journal:  Circulation       Date:  2004-09-27       Impact factor: 29.690

8.  Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172.

Authors:  D Fegley; S Kathuria; R Mercier; C Li; A Goutopoulos; A Makriyannis; D Piomelli
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-11       Impact factor: 11.205

9.  Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta.

Authors:  E Herradón; M I Martín; V López-Miranda
Journal:  Br J Pharmacol       Date:  2007-08-20       Impact factor: 8.739

10.  Delta9-tetrahydrocannabinol (THC) and AM 404 protect against cerebral ischaemia in gerbils through a mechanism involving cannabinoid and opioid receptors.

Authors:  A Zani; D Braida; V Capurro; M Sala
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.